(S)-N-(1-(5-bromo-2-((cyclopropylmethyl)amino)pyrimidin-4-yl)-2-(3,5-difluorophenyl)ethyl)-2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamide → (S)-5-(2-((cyclopropylmethyl)amino)-4-(1-(2-(3-(difluoromethyl)-4,4,7,7-tetrafluoro-4,5,6,7-tetrahydro-1H-indazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)pyrimidin-5-yl)-2-fluorobenzamide

Participants

Reaction Steps

The title compound (13B) was prepared according to the method presented for the synthesis of compound 11J of Example 11 utilizing 13A. 1H NMR (400 MHz, CD3OD) δ 8.50 (d, J=7.7 Hz, 1H), 7.73 (s, 1H), 7.24-7.02 (m, 2H), 6.90 (dd, J=10.7, 8.6 Hz, 1H), 6.65-6.24 (m, 2H), 6.13 (d, J=6.1 Hz, 2H), 4.91 (m, 1H), 4.83-4.62 (m, 2H), 3.09 (m, 2H), 2.71 (ddd, J=20.2, 13.3, 7.4 Hz, 2H), 2.37-2.06 (m, 4H), 0.88 (m, 1H), 0.47-0.16 (m, 2H), 0.02 (q, J=5.1 Hz, 2H). MS (m/z) 726.30 [M+H]+.

Provenance & Evidence